{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:54:51Z","timestamp":1791449691907,"version":"4.3.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41366-026-02096-1","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:12:12Z","timestamp":1777702332000},"page":"1891-1892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Obesity paradox in young with myocardial infarction in China \u2013 or is this really a lean paradox?"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3906-1911","authenticated-orcid":false,"given":"Carl J.","family":"Lavie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vince","family":"Catalfamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"2096_CR1","first-page":"1676","volume":"41","author":"CJ Lavie","year":"2025","unstructured":"Lavie CJ, Tutor AW, Carbone S. Is the obesity paradox real? Can J Cardiol. 2025;41:1676\u20138.","journal-title":"Can J Cardiol"},{"key":"2096_CR2","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1136\/heartjnl-2015-307966","volume":"101","author":"CJ Lavie","year":"2015","unstructured":"Lavie CJ, De Schutter A, Milani RV. Body composition and the obesity paradox in coronary heart disease: can heavier really be healthier? Heart. 2015;101:1610\u20131.","journal-title":"Heart"},{"key":"2096_CR3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","volume":"44","author":"JH Butt","year":"2023","unstructured":"Butt JH, Petrie MC, Jhund PS, Sattar N, Desai AS, K\u00f8ber L, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023;44:1136\u201353.","journal-title":"Eur Heart J"},{"key":"2096_CR4","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221\u201332.","journal-title":"N Engl J Med"},{"key":"2096_CR5","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","volume":"406","author":"J Deanfield","year":"2025","unstructured":"Deanfield J, Lincoff AM, Kahn SE, Emerson SS, Lingvay I, Scirica BM, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet. 2025;406:2257\u201368.","journal-title":"Lancet"},{"key":"2096_CR6","doi-asserted-by":"publisher","unstructured":"Zhang L, Liu Z, Zeng J, Wu M. Age-dependent obesity paradox in acute myocardial infarction prognosis: a cohort study of Body Mass Index and Recurrent Myocardial Infarction. Int J Obes. 2026. https:\/\/doi.org\/10.1038\/s41366-026-02038-x.","DOI":"10.1038\/s41366-026-02038-x"},{"key":"2096_CR7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/ejhf.576","volume":"18","author":"E Zamora","year":"2016","unstructured":"Zamora E, Lup\u00f3n J, Enjuanes C, Pascual-Figal D, de Antonio M, Domingo M, et al. No benefit from the obesity paradox for diabetic patients with heart failure. Eur J Heart Fail. 2016;18:851\u20138.","journal-title":"Eur J Heart Fail"},{"key":"2096_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.mayocp.2012.01.013","volume":"87","author":"PA McAuley","year":"2012","unstructured":"McAuley PA, Artero EG, Sui X, Lee DC, Church TS, Lavie CJ, et al. The obesity paradox, cardiorespiratory fitness, and coronary heart disease. Mayo Clin Proc. 2012;87:443\u201351.","journal-title":"Mayo Clin Proc"},{"key":"2096_CR9","doi-asserted-by":"publisher","unstructured":"Lavie CJ, Neeland IJ, Carbone S, Heymsfield SB. Directly measured fat mass and heart failure prognosis-a new twist in the obesity paradox. Can J Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.cjca.2026.01.030.","DOI":"10.1016\/j.cjca.2026.01.030"},{"key":"2096_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4065\/mcp.2011.0092","volume":"86","author":"CJ Lavie","year":"2011","unstructured":"Lavie CJ, De Schutter A, Patel D, Artham SM, Milani RV. Body composition and coronary heart disease mortality\u2014an obesity or a lean paradox? Mayo Clin Proc. 2011;86:857\u201364.","journal-title":"Mayo Clin Proc"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02096-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02096-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02096-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:31:41Z","timestamp":1791448301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-026-02096-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1038\/s41366-026-02096-1","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CJL is on the DSMB for Novo Nordisk for the REDEFINE 3 Trial with Cagri Sema. VC and SC do not have any conflicts.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}